Ifosfamide, methotrexate, and vincristine (IMV) combination chemotherapy as secondary treatment for patients with malignant lymphoma.
D003520:Cyclophosphamide / Q000031:analogs & derivatives*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage* / Q000009:adverse effects; D008223:Lymphoma / Q000188:drug therapy* / Q000401:mortality; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects; D014750:Vincristine / Q000008:administration & dosage* / Q000009:adverse effects
D014750:Vincristine; D003520:Cyclophosphamide; D007069:Ifosfamide; D008727:Methotrexate